October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Cancer Incidence Increasing Across Age Groups, Global Study Finds

15-year registry analysis examines cancer patterns by age in 42 populations worldwide.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

New Criteria, New Numbers on Obesity

A Lancet Commission definition integrating BMI with anthropometric measures increased obesity prevalence by ~60% in a major US cohort, identifying previously unrecognized high-risk patients while introducing distinct clinical phenotypes.

Conexiant

October 16, 2025

Comprehensive Review Identifies Key Neonatal Death Risks

Review grades evidence on neonatal mortality across 64 reviews; methods and gaps outlined.

Conexiant

October 15, 2025

Medical Oddities: The Half-Hour Health Hack

Metabolic tweaks, sensory sweet spots, antiviral spice, and a soothing cup for the heart and more this week.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 14, 2025

Breast Screening: The Age Question

Screening every two years offers greater life-year gains in breast cancer care.

Conexiant

October 10, 2025

Lobular Breast Cancer Rates Rising Nationwide, Study Shows

Lobular breast cancers present larger, HR-positive tumors and lower long-term survival rates.

Conexiant